Subscribe

CSPC

CSPC
HKEX

Biomedical R&D company

OVERVIEW

Categories
Healthcare, Biopharmaceutical, Medical, Pharmaceutical R&D, Traditional Chinese Medicine Patent Prescription
HQ location
Hebei
Founded date
Jun. 16, 1992
IPO date
Jun. 21, 1994
Legal name
Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC) 
Email
CSPC is a biopharmaceutical R & D company, which has three business segments, i.e. innovative medicine, general medicine and API. It is mainly engaged in the development, production and sales of medicine and related products. The proprietary products mainly include antibiotics, cardio cerebrovascular medicine, antipyretic and analgesic medicine, digestive system medicine, anti-tumor medicine and Chinese patent medicine. The API products mainly include antibiotics, vitamin C and coffee Caffeine series.
01093:HKEX
Transaction date
Jun. 2, 2020
52-week high
HKD 21.80
52-week low
HKD 11.22
Volume
974,970,007
Open
HKD 15.76
Close
HKD 16.38
P/E
23.80
Market cap
HKD 102.15 billion

ANALYSIS

Heavily sold over $ 1 billion in heavy products and sold for $ 13.4 billion! Is Shiyao preemptive without opponents?

The application for the listing of generic copy of Apster tablets of CSPC is accepted by CDE and is currently under review and approval. Apster tablets are heavyweight products of Xinji Pharmaceutical, which were later acquired by Amgen at a high price. At present, there is no such product imported or generic drugs listed on the domestic market. CSPC Europe is also the only pharmaceutical company currently applying for listing

Mar. 25, 2020 · CSPC

The two times that CSPC "divided" from innovative pharmaceutical companies, what is the crux of the problem?

Shenzhou Cell had previously reached a commercial agreement with CSPC on the product under study SCT400, but based on the changes in the pharmaceutical policy and market environment in the past year, CSPC proposed to Shenzhou Cell to modify the "Commercialization Agreement". Follow-up did not reach agreement on the amendment of the agreement. . CSPC just ended its cooperation with another innovative pharmaceutical company, Junshi Biology. On December 30, CSPC issued an announcement that in order to avoid potential conflicts that may arise from clinical research and future commercialization of another anti-PD-1 monoclonal antibody drug under investigation, the company and Junshi Zao The previously signed cooperation on R & D and commercialization of breast cancer drugs was concluded on December 30, 2019.

Jan. 9, 2020 · CSPC

CSPC, Fosun, WuXi PharmaTech, Xinhecheng, 4 pharmaceutical companies were listed as "Outstanding Leaders in Multinational Management"

Forbes China launched the "Outstanding Leaders of Chinese Enterprises' Multinational Operations" list for the first time. Of the 50 outstanding Chinese business leaders, 4 of them are from the pharmaceutical industry. They are Cai Dongchen, Xinhecheng's Hu Baiyan and WuXi of CSPC. Li Ge of Kant and Wu Yifang of Fosun Pharma.

Oct. 9, 2019 · CSPC

REPORTS

CSPC (1093.HK): Stable annual report performance, strong growth of NBP and tumor line

Based on the company ’s lower-than-expected annual report performance, the net profit attributable to mothers in 2020-2021 was lowered from 47.33 and 64.77 to 4.331 billion and 5.072 billion yuan, and the net profit attributable to mothers in 2022 was increased by 6.012 billion yuan, up 16.6% and 17.1% year-on-year. 18.5%

Apr. 1, 2020 · CSPC

CSPC (1093.HK): Performance is in line with expectations, and gradually strengthen innovation

It is estimated that the company's net profit attributable to the mother in 2020-2022 will be 4.33 billion yuan, 5.19 billion yuan and 6.134 billion yuan respectively, with corresponding growth rates of 16.6%, 19.8% and 18.3%, and EPS of 0.69 yuan / share and 0.83 yuan / share. Shares and 0.98 yuan / share

Mar. 31, 2020 · CSPC
  • Company Details
  • Related Companies
  • EO Analysis
Overview
Categories
Healthcare, Biopharmaceutical, Medical, Pharmaceutical R&D, Traditional Chinese Medicine Patent Prescription
HQ location
Hebei
Founded date
Jun. 16, 1992
IPO date
Jun. 21, 1994
Legal name
Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC) 
Email
CSPC is a biopharmaceutical R & D company, which has three business segments, i.e. innovative medicine, general medicine and API. It is mainly engaged in the development, production and sales of medicine and related products. The proprietary products mainly include antibiotics, cardio cerebrovascular medicine, antipyretic and analgesic medicine, digestive system medicine, anti-tumor medicine and Chinese patent medicine. The API products mainly include antibiotics, vitamin C and coffee Caffeine series.
01093:HKEX
Transaction date
Jun. 2, 2020
52-week high
HKD 21.80
52-week low
HKD 11.22
Volume
974,970,007
Open
HKD 15.76
Close
HKD 16.38
P/E
23.80
Market cap
HKD 102.15 billion
Analysis

Heavily sold over $ 1 billion in heavy products and sold for $ 13.4 billion! Is Shiyao preemptive without opponents?

The application for the listing of generic copy of Apster tablets of CSPC is accepted by CDE and is currently under review and approval. Apster tablets are heavyweight products of Xinji Pharmaceutical, which were later acquired by Amgen at a high price. At present, there is no such product imported or generic drugs listed on the domestic market. CSPC Europe is also the only pharmaceutical company currently applying for listing

Mar. 25, 2020 · CSPC

The two times that CSPC "divided" from innovative pharmaceutical companies, what is the crux of the problem?

Shenzhou Cell had previously reached a commercial agreement with CSPC on the product under study SCT400, but based on the changes in the pharmaceutical policy and market environment in the past year, CSPC proposed to Shenzhou Cell to modify the "Commercialization Agreement". Follow-up did not reach agreement on the amendment of the agreement. . CSPC just ended its cooperation with another innovative pharmaceutical company, Junshi Biology. On December 30, CSPC issued an announcement that in order to avoid potential conflicts that may arise from clinical research and future commercialization of another anti-PD-1 monoclonal antibody drug under investigation, the company and Junshi Zao The previously signed cooperation on R & D and commercialization of breast cancer drugs was concluded on December 30, 2019.

Jan. 9, 2020 · CSPC

CSPC, Fosun, WuXi PharmaTech, Xinhecheng, 4 pharmaceutical companies were listed as "Outstanding Leaders in Multinational Management"

Forbes China launched the "Outstanding Leaders of Chinese Enterprises' Multinational Operations" list for the first time. Of the 50 outstanding Chinese business leaders, 4 of them are from the pharmaceutical industry. They are Cai Dongchen, Xinhecheng's Hu Baiyan and WuXi of CSPC. Li Ge of Kant and Wu Yifang of Fosun Pharma.

Oct. 9, 2019 · CSPC
Reports

CSPC (1093.HK): Stable annual report performance, strong growth of NBP and tumor line

Based on the company ’s lower-than-expected annual report performance, the net profit attributable to mothers in 2020-2021 was lowered from 47.33 and 64.77 to 4.331 billion and 5.072 billion yuan, and the net profit attributable to mothers in 2022 was increased by 6.012 billion yuan, up 16.6% and 17.1% year-on-year. 18.5%

Apr. 1, 2020 · CSPC

CSPC (1093.HK): Performance is in line with expectations, and gradually strengthen innovation

It is estimated that the company's net profit attributable to the mother in 2020-2022 will be 4.33 billion yuan, 5.19 billion yuan and 6.134 billion yuan respectively, with corresponding growth rates of 16.6%, 19.8% and 18.3%, and EPS of 0.69 yuan / share and 0.83 yuan / share. Shares and 0.98 yuan / share

Mar. 31, 2020 · CSPC